Cagrilintide
In clinical trialsAlso known as: Cagri, CagriSema (when combined with semaglutide)
Category: Weight & metabolic
Sold as:
Ameano Peptides: Cagrilintide
Nexaph: Cagrilintide
Long-acting amylin analog that increases fullness after meals. It works on a different pathway from GLP-1 drugs and is mostly studied paired with semaglutide.
What it's used for
- Obesity (investigational)
- Type 2 diabetes (investigational)
- Combined with semaglutide as CagriSema for larger weight loss
Dosing
- Typical dose
- Trial protocols started at 0.25 mg weekly and increased every 4 weeks through 0.5, 1, and 1.7 mg to a 2.4 mg weekly maintenance dose. In CagriSema trials it was given with matching semaglutide doses. No approved dose exists.
- How often
- Once weekly
- Route
- Subcutaneous injection
- Cycle length
- Trial durations were 68 weeks or longer
Build a dosing plan for Cagrilintide →
How to reconstitute and measure a dose → · About bacteriostatic water →
Possible side effects
- Nausea, constipation, vomiting, diarrhea
- Fatigue and reduced appetite
- Injection site reactions
Important: Not FDA-approved. Anything sold outside clinical trials or a licensed pharmacy is unregulated, and purity cannot be assumed. Stacking it with a GLP-1 drug increases GI side effects, so titrate slowly.
Also sold in blends
- Reta/Cagri Blend: Retatrutide 12.5 mg + Cagrilintide 2.5 mg (Ameano Peptides)